Chemical and Biological Defense Program - Dem/Val

Abstract

This program element (PE) resources Advanced Component Development and Prototypes across the Understand, Protect, Mitigate, and Enabling Investments portfolios. Program efforts validate high-risk/high-payoff technologies and their respective concepts of operations for significant improvement to Warfighter capabilities in preparation for the transition of mature technologies to advanced development programs requiring chemical and biological (CB) defense technologies. Chemical Biological Defense Program (CBDP) investments provide an integrated, layered capability to enable Countering Weapons of Mass Destruction (CWMD) missions ranging from combat operations to Department of Defense (DoD) support to domestic incident prevention and response. The Projects in this PE support component and subsystem maturity prior to integration in major, complex systems and may involve risk reduction initiatives and include technology demonstrations. This effort facilitates transitions of Integrated Early Warning and Integrated Layered Defense products. FY24 funding accelerates characterization and situational awareness of emerging biothreats and accelerates delivery of improved protection from and mitigation of biothreats, including rapid repurposing of available therapeutics and development of new vaccines. Individual Projects include: - Understand (UN4): Maintain effort in distinguishing between bacterial, viral, and toxin diagnostics. Update detector libraries for relevant detection and identification systems. Continue efforts to integrate detection capabilities into Service combat platforms. Develop detection and diagnostic technologies with compatibility to receive and transmit sensor data on Service networks. Identify Service concepts for Integrated Early Warning (IEW) and maintain cyber compliance of fielded Chemical Biological Radiological and Nuclear (CBRN) information systems. - Protect (PT4): Continued efforts to unencumber the warfighter by delivering improved personal protection capabilities that incorporate inherent survivability into Service equipment and platforms and which offer protection against the diverse threat agents that near-peer adversaries are developing. Develop capability for next-generation individual protective equipment. In collaboration with Biomedical Advanced Research and Development Authority (BARDA), develops and tests monoclonal antibody medical countermeasures through Phase 1 clinical trials as an accelerated antibodies program. Develops a robust computational toolset/prototype database intended to decrease product development risk throughout the drug development life cycle, accelerate candidate development, and enable preemptive preparedness and rapid response. Leveraging the Advanced Development Manufacturing Network, delivers the ability to rapidly develop Medical Countermeasures (MCMs) against emerging or known chemical/biological threats by establishing mature platform technologies that allow for rapid response. Develops plague monoclonal antibody-based medical countermeasure prototype through Phase 1 clinical testing. Continues work to deliver prototype nucleic acid-based vaccines for three CBRN and two potential pandemic threats through non-clinical and human Phase I clinical trials. - Mitigate (MT4): Sustain efforts in antiviral therapeutics. Develop capabilities to incorporate the use of in silico and Machine Learning/Artificial Intelligence technologies for drug discovery and development. Increase efforts regarding platform technologies. Development of repurposing pharmaceuticals that enable a rapid response capability to combat emerging threats. Supports the development of robot decontamination platform systems. Completes prototype development for a sprayable slurry Science & Technology (S&T) transition to decontaminate hardened and sensitive equipment, such as weapon system optics, electronic equipment and spot decontamination on vehicles. Continues prototype development for S&T transitions for tactical temporary coatings that mitigate the effects of a CBRN attack by protecting assets from the effects of chemical warfare agents. - Enabling Investments (EN4): Development of efforts to evaluate integrated technologies or prototype systems in high fidelity and realistic operating environment, including system-specific efforts that help expedite technology transition from the laboratory to operational use. Increase efforts to improve integration of collective protection into Service major combat platforms. - Contamination Avoidance (CA4), Decontamination (DE4), Individual Protection (IP4), Medical Biological Defense (MB4), Techbase Medical Defense (TM4) and Technology Transition (TT4) are no longer active FY24 Projects due to budget restructuring. The projects in this PE support the advanced component technology development phase of the DoD acquisition system and are therefore correctly placed in Budget Activity 4.

Open PDF

Document Details

Document Type
R2 Budgetary Justification
Publication Date
Oct 01, 2024
Source ID
0603884BP_4_0400_PB_2024
Change Summary Explanation
Funding: FY 2022 (+$4.500 Million): Congressional Add for development of medical countermeasures against novel entities (DOMANE) is reflected in the Previous President's Budget total. FY 2022 (+$3.700 Million): Below threshold reprogramming increase supports advanced emerging threat defense and rapid monoclonal antibody development. FY 2022 (-$3.742 Million): Transfer of funding to support Small Business Innovative Research/Small Business Technology Transfer efforts. FY 2023 (-$39.354 Million): Congressional Directed Reductions. FY 2024 ($55.614 Million): Increase for medical countermeasure manufacturing optimization (+$38.100 Million), Departmental inflation rate adjustments (+$1.266 Million); and Compact Vapor Chemical Agent Detector activities in support of MS B, Antiviral Oral Therapeutic natural history study, Reactivating Nerve Agent Treatment System animal model development, and additional enhanced biodefense priority efforts (+$16.248 Million). Schedule: N/A Technical: Provides for critical new start programs Advanced Differential Diagnostics (ADD), Automated Decon System (ADS), Antiviral Oral Therapeutic (AVO TX), Botulinum Toxin Treatment program (BOT Tx), Consolidated Nerve Agent Treatment System (CNATS), Colorimetric Indicator (C-IND), Physiological Monitoring Sensor Suite (PM2S), and the Reactivating Nerve Agent Treatment System (RNATS).
Service Agency Name
Chemical and Biological Defense Program

Tags

Communities of Interest

  • Biomedical

DTIC Thesaurus Topics

  • Artificial Intelligence
  • Chemical Detection
  • Chemical Warfare
  • Chemical Warfare Agents
  • Chemical Weapons
  • Command And Control
  • Covid-19
  • Detection
  • Detectors
  • Identification Systems
  • Infectious Diseases
  • Information Systems
  • Medical Personnel
  • Personal Protective Equipment
  • Systems Engineering
  • Test And Evaluation
  • Warfare

Readers

  • Critical Infrastructure Protection in CBRN and WMD Threats.
  • Military Science and Technology Research and Modernization.

Technology Areas

  • AI & ML
  • AI & ML - DoD AI Strategy
  • Autonomy
  • Biotechnology
  • Cyber
  • Microelectronics

Related Documents